Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00555672
First received: November 8, 2007
Last updated: December 12, 2011
Last verified: December 2011
Results First Received: December 15, 2010  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Stomach Neoplasms
Interventions: Drug: 5-fluorouracil
Drug: cisplatin
Drug: sunitinib malate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sunitinib (25 mg) in Combination With Cisplatin and 5-FU Sunitinib: 25 milligram (mg) oral capsule daily for 2 weeks (Day 1 to 14) followed by 1 week (Day 15 to 21) off treatment. Cisplatin: 80 mg per meter squared (mg/m^2) intravenous on Day 1 of each 21-day cycle. 5-Fluorouracil (5-FU): 4000 mg/m^2 continuous infusion for 96 hours starting Day 1 and ending Day 5 of each 21-day cycle.
Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU Sunitinib: 37.5 mg oral capsule daily for 2 weeks (Day 1 to 14) followed by 1 week (Day 15 to 21) off treatment. Cisplatin: 80 mg per meter squared (mg/m^2) on Day 1 of each 21-day cycle. 5-Fluorouracil (5-FU): 4000 mg/m^2 continuous infusion for 96 hours starting Day 1 and ending Day 5 of each 21-day cycle.

Participant Flow:   Overall Study
    Sunitinib (25 mg) in Combination With Cisplatin and 5-FU     Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU  
STARTED     24     10  
COMPLETED     0     0  
NOT COMPLETED     24     10  
Death                 0                 2  
Adverse Event                 8                 2  
Objective progression or relapse                 11                 5  
Unspecified                 3                 1  
Participant refused                 2                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sunitinib (25 mg) in Combination With Cisplatin and 5-FU Sunitinib: 25 milligram (mg) oral capsule daily for 2 weeks (Day 1 to 14) followed by 1 week (Day 15 to 21) off treatment. Cisplatin: 80 mg per meter squared (mg/m^2) intravenous on Day 1 of each 21-day cycle. 5-Fluorouracil (5-FU): 4000 mg/m^2 continuous infusion for 96 hours starting Day 1 and ending Day 5 of each 21-day cycle.
Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU Sunitinib: 37.5 mg oral capsule daily for 2 weeks (Day 1 to 14) followed by 1 week (Day 15 to 21) off treatment. Cisplatin: 80 mg per meter squared (mg/m^2) on Day 1 of each 21-day cycle. 5-Fluorouracil (5-FU): 4000 mg/m^2 continuous infusion for 96 hours starting Day 1 and ending Day 5 of each 21-day cycle.
Total Total of all reporting groups

Baseline Measures
    Sunitinib (25 mg) in Combination With Cisplatin and 5-FU     Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU     Total  
Number of Participants  
[units: participants]
  24     10     34  
Age  
[units: years]
Mean ± Standard Deviation
  60.1  ± 12.0     56.4  ± 10.4     59.0  ± 11.5  
Gender  
[units: participants]
     
Female     7     4     11  
Male     17     6     23  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)   [ Time Frame: Cycle 1 (Baseline to Day 21) ]

2.  Secondary:   Maximum Observed Plasma Concentration (Cmax)   [ Time Frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose) ]

3.  Secondary:   Area Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)]   [ Time Frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours postdose) ]

4.  Secondary:   Time to Reach Maximum Observed Plasma Concentration (Tmax)   [ Time Frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose) ]

5.  Secondary:   Steady State Concentration (Css) of 5-Fluorouracil (5-FU)   [ Time Frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion) ]

6.  Secondary:   Infusion Rate (Zero Order) (R0) of 5-FU   [ Time Frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion) ]

7.  Secondary:   Clearance (CLss) of 5-FU   [ Time Frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion) ]

8.  Secondary:   Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU   [ Time Frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion) ]

9.  Secondary:   Number of Participants With Objective Response   [ Time Frame: Baseline, Day 21 of every even-numbered cycle up to 15 Months ]

10.  Secondary:   Duration of Response (DR)   [ Time Frame: Baseline up to Month 15 ]

11.  Secondary:   Progression-Free Survival (PFS)   [ Time Frame: Baseline up to Month 15 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00555672     History of Changes
Other Study ID Numbers: A6181128
Study First Received: November 8, 2007
Results First Received: December 15, 2010
Last Updated: December 12, 2011
Health Authority: United States: Food and Drug Administration